FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037829609> ?p ?o ?g. }

• W2037829609 endingPage "213" @default.
• W2037829609 startingPage "207" @default.
• W2037829609 abstract "Objectives In vitro studies have shown synergistic anti-myeloma effects of bortezomib combined with alkylating agents or anthracycline. We tested safety and efficacy of the combination of bortezomib, doxorubicin cyclophosphamide, and dexamethasone (ABCD) in the treatment of relapsed/refractory myeloma. Methods ABCD consisted of bortezomib given intravenous (IV) at dosage 1.3 mg/m2, dexamethasone 40 mg IV on days 1, 4, 8, and 15, pegylated liposomal doxorubicin (PLD) 20 mg IV on days 1 and 15, plus cyclophosphamide 100 mg/d per os for 15 d. Between January 2008 and February 2009, 24 patients received a median of four 28-d ABCD cycles (range 1–6). All patients had been already treated with a median of two previous lines of treatment (range 1–6): 38% were resistant to previous therapies and 62% were relapsed. Results Clinical response was observed in 12 patients (50%), including 29% of very good partial remissions or better. Side effects included hematological toxicity (31% any grade), grades 3–4 thrombocytopenia (9%), grades 3–4 anemia (17%). Non-hematological toxicity affected 32% of administered cycles and included gastrointestinal disturbances (54%), peripheral neuropathy (8%), and infections (8%). After a median follow-up of 21.5 months (range 2–44 months), median of progression-free survival (PFS) was 8.7 months and median overall survival was 22.5 months. Achieving at least partial response within the second cycle was associated with a better PFS (19.5 months vs. 3.5 months), P = 0.03, HR 0.35 (CI 95% 0.13–0.90). Conclusion ABCD is safe and effective for relapsed/refractory MM subjects previously treated with novel agents." @default.
• W2037829609 created "2016-06-24" @default.
• W2037829609 creator A5003679742 @default.
• W2037829609 creator A5007490809 @default.
• W2037829609 creator A5018769545 @default.
• W2037829609 creator A5034393745 @default.
• W2037829609 creator A5034992947 @default.
• W2037829609 creator A5038163660 @default.
• W2037829609 creator A5039414535 @default.
• W2037829609 creator A5060107199 @default.
• W2037829609 creator A5061788416 @default.
• W2037829609 date "2014-04-18" @default.
• W2037829609 modified "2023-09-25" @default.
• W2037829609 title "Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients" @default.
• W2037829609 cites W1555222912 @default.
• W2037829609 cites W173435793 @default.
• W2037829609 cites W1966163309 @default.
• W2037829609 cites W1975539073 @default.
• W2037829609 cites W1990969204 @default.
• W2037829609 cites W1992083467 @default.
• W2037829609 cites W2003734726 @default.
• W2037829609 cites W2009548081 @default.
• W2037829609 cites W2026157340 @default.
• W2037829609 cites W2032057743 @default.
• W2037829609 cites W2039217634 @default.
• W2037829609 cites W2044436186 @default.
• W2037829609 cites W2056236957 @default.
• W2037829609 cites W2059568170 @default.
• W2037829609 cites W2076668534 @default.
• W2037829609 cites W2083480184 @default.
• W2037829609 cites W2100890240 @default.
• W2037829609 cites W2106379961 @default.
• W2037829609 cites W2108235071 @default.
• W2037829609 cites W2108826965 @default.
• W2037829609 cites W2127180422 @default.
• W2037829609 cites W2127760782 @default.
• W2037829609 cites W2133389067 @default.
• W2037829609 cites W2136795385 @default.
• W2037829609 cites W2142195688 @default.
• W2037829609 doi "https://doi.org/10.1111/ejh.12325" @default.
• W2037829609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24673398" @default.
• W2037829609 hasPublicationYear "2014" @default.
• W2037829609 type Work @default.
• W2037829609 sameAs 2037829609 @default.
• W2037829609 citedByCount "11" @default.
• W2037829609 countsByYear W20378296092014 @default.
• W2037829609 countsByYear W20378296092015 @default.
• W2037829609 countsByYear W20378296092016 @default.
• W2037829609 countsByYear W20378296092017 @default.
• W2037829609 countsByYear W20378296092018 @default.
• W2037829609 countsByYear W20378296092019 @default.
• W2037829609 countsByYear W20378296092020 @default.
• W2037829609 crossrefType "journal-article" @default.
• W2037829609 hasAuthorship W2037829609A5003679742 @default.
• W2037829609 hasAuthorship W2037829609A5007490809 @default.
• W2037829609 hasAuthorship W2037829609A5018769545 @default.
• W2037829609 hasAuthorship W2037829609A5034393745 @default.
• W2037829609 hasAuthorship W2037829609A5034992947 @default.
• W2037829609 hasAuthorship W2037829609A5038163660 @default.
• W2037829609 hasAuthorship W2037829609A5039414535 @default.
• W2037829609 hasAuthorship W2037829609A5060107199 @default.
• W2037829609 hasAuthorship W2037829609A5061788416 @default.
• W2037829609 hasConcept C121332964 @default.
• W2037829609 hasConcept C121608353 @default.
• W2037829609 hasConcept C126322002 @default.
• W2037829609 hasConcept C141071460 @default.
• W2037829609 hasConcept C142424586 @default.
• W2037829609 hasConcept C2776364478 @default.
• W2037829609 hasConcept C2776694085 @default.
• W2037829609 hasConcept C2776755627 @default.
• W2037829609 hasConcept C2776802502 @default.
• W2037829609 hasConcept C2777478702 @default.
• W2037829609 hasConcept C2780401358 @default.
• W2037829609 hasConcept C29730261 @default.
• W2037829609 hasConcept C530470458 @default.
• W2037829609 hasConcept C71924100 @default.
• W2037829609 hasConcept C87355193 @default.
• W2037829609 hasConcept C90924648 @default.
• W2037829609 hasConceptScore W2037829609C121332964 @default.
• W2037829609 hasConceptScore W2037829609C121608353 @default.
• W2037829609 hasConceptScore W2037829609C126322002 @default.
• W2037829609 hasConceptScore W2037829609C141071460 @default.
• W2037829609 hasConceptScore W2037829609C142424586 @default.
• W2037829609 hasConceptScore W2037829609C2776364478 @default.
• W2037829609 hasConceptScore W2037829609C2776694085 @default.
• W2037829609 hasConceptScore W2037829609C2776755627 @default.
• W2037829609 hasConceptScore W2037829609C2776802502 @default.
• W2037829609 hasConceptScore W2037829609C2777478702 @default.
• W2037829609 hasConceptScore W2037829609C2780401358 @default.
• W2037829609 hasConceptScore W2037829609C29730261 @default.
• W2037829609 hasConceptScore W2037829609C530470458 @default.
• W2037829609 hasConceptScore W2037829609C71924100 @default.
• W2037829609 hasConceptScore W2037829609C87355193 @default.
• W2037829609 hasConceptScore W2037829609C90924648 @default.
• W2037829609 hasIssue "3" @default.
• W2037829609 hasLocation W20378296091 @default.
• W2037829609 hasLocation W20378296092 @default.
• W2037829609 hasOpenAccess W2037829609 @default.

• next